腎疾患に対する様々なソリューションを研究開発し、腎疾患に苦しむ患者さんのQuality of Lifeの改善により社会に貢献する
Location: Japan
Total raised: $10.6M
Investors 1
| Date | Name | Website |
| - | J-Startup | j-startup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.07.2026 | - | $10.6M | Jafco |
Mentions in press and media 13
| Date | Title | Description |
| 23.07.2026 | Rege Nephro Secures $10.6 Million for Kidney Disease Innovations | Rege Nephro, a pioneering biotechnology firm, has secured approximately $10.6 million in new financing. This crucial capital propels its innovative kidney disease pipeline. Funds will advance RN-014, a lead candidate for Autosomal Dominant ... |
| 21.07.2026 | Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization | Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechno... |
| 21.07.2026 | Rege Nephro Raises $10.6 Million To Advance RN-014 And Kidney Regeneration Pipeline | Rege Nephro has raised approximately $10.6 million to advance its kidney disease programs, including lead candidate RN-014 and regenerative medicine program RN-032. The clinical-stage biotechnology company completed the financing through th... |
| 15.04.2025 | Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials | KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets ... |
| 07.10.2024 | Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials | KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully developed a funding plan of total 25 billion yen in new Series B funding and raised 22... |
| 28.05.2024 | Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD | KYOTO, Japan, May 28, 2024 /PRNewswire/ -- Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental p... |
| 27.05.2024 | Regenefro Co., Ltd. Regenefro begins recruiting subjects for the second stage of the early phase II clinical trial of its ADPKD treatment drug | - |
| 27.05.2024 | Regenefro Co., Ltd. Regenefro begins recruiting subjects for the second stage of the early phase II clinical trial of its ADPKD treatment drug | Regenefro Co., Ltd. Regenefro begins recruiting subjects for the second stage of early phase 2 clinical trial of ADPKD treatment drug …… Regenephro Co., Ltd. (https://www.regenephro.co.jp/) will begin recruiting subjects from April for the ... |
| 18.01.2024 | AstraZeneca K.K. Developed a method for selectively inducing differentiation of renal interstitial progenitor cells from human iPS cells, and succeeded in producing kidney tissue with a glomerular mes... | - |
| 18.01.2024 | AstraZeneca K.K. Developed a method for selectively inducing differentiation of renal interstitial progenitor cells from human iPS cells, and succeeded in producing kidney tissue with a glomerular mes... | AstraZeneca Ltd. Developed a method for selectively inducing the differentiation of renal interstitial progenitor cells from human iPS cells, and succeeded in producing kidney tissue with a glomerular mesangial structure in vitro for the fi... |
Show more